Searched for
MD SIDDHARTH MITTAL
Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: Syngene MDThe recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...- Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps downBiocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...
- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- Biocon gets CDSCO nod for generic diabetes medicationBiocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Ty...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Biocon Q4 Results: Net profit slumps 57% YoY to Rs 135 croreBiocon Q4 Results: Revenue from operations increased 16% year-on-year (YoY) to Rs 2,947 crore in the January-March 2024 period.
- Biocon partners Biomm to commercialise diabetes drug in BrazilBiocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...
- Biocon appoints Peter Bains as Group CEO"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...
- Indifi Technologies raises Series E funding of $35 millionThe funds raised by the company would be used to develop new lending products, increase customer access, and enable more segments.
- Biocon shares jump 8% post Q4 results. Is the Street happy?Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings growth. Net profit grew by 31% to INR 313 crore with 57% YoY growth in co...
- Biocon Q4 Results: Cons PAT grows 31% YoY to Rs 313 crore, revenue surges 57%The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew almost 37% to Rs 11,174 crore, while...
- Demand for luxury homes may rise in short termStartup founders and company promoters looking to save on taxes have emerged as the main buyers of super luxury real estate properties afte...
- Biocon ties up with Tabuk Pharmaceuticals to commercialise speciality medicines in Middle EastUnder the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products of Biocon and...
- Biocon elevates Siddharth Mittal as CEO and joint MDMittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30.
- Biocon Q2 net profit at Rs 216 croreConsolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration.
- After ED, CBI moves Delhi HC against acquittal of A Raja, Kanimozhi in 2G caseBesides Raja and Kanimozhi, the special court had on December 21 last year acquitted 17 others, including DMK supremo M Karunanidhi's wife ...
- LetsMD gets a fresh Angel-funding shot"LetsMD will enable accessibility and affordability of tertiary level healthcare in India. We believe CAN, with its large and diverse netwo...
- Bricks-and-mortar biggies start bonding with startupsThe lure of high returns and ease of making bite-size investments through new funds draw old businesses to startups
- Politicians, CEOs & Bollywood - a starry turnout at Chanda Kochhar daughter's weddingThe ceremony was telecast live on giant LED screens. The guests were given a booklet of the entire ceremony and the mantras so that they co...
- MNCs stick with plan for captive BPO units hereStandard Chartered, SuperValu, JP Morgan and Deutsche Bank are going ahead with expansion of their IT/BPO centres in India. Top Indian outs...
Load More
